Arrowhead Says Redemplo to Become New NHS Treatment Option for FCS

Arrowhead Pharmaceuticals said adults with familial chylomicronaemia syndrome in England and Wales will have access to Redemplo (plozasiran), a newly licensed treatment option on the NHS to reduce triglycerides.